Immune Thrombocytopenia: A Comprehensive Review of Pathophysiology, Epidemiology, Diagnosis, Treatment, and Management Strategies

Abstract

Immune Thrombocytopenia (ITP) stands as a complex, acquired autoimmune disorder, specifically characterized by isolated thrombocytopenia attributed to a multifaceted interplay of accelerated platelet destruction and impaired megakaryopoiesis and platelet production. This comprehensive and in-depth review meticulously explores the intricate pathophysiology underpinning ITP, ranging from autoantibody-mediated mechanisms to the pivotal roles of cellular immunity and genetic predispositions. It further delves into the global epidemiology of the condition, highlighting its bimodal age distribution and varying clinical presentations. Significant emphasis is placed on the formidable diagnostic challenges inherent to ITP, necessitating a rigorous exclusion of numerous secondary causes of thrombocytopenia. The report subsequently elucidates the natural course of both acute and chronic forms of the disease, underscoring their distinct prognoses and impacts on patients. A substantial portion is dedicated to a detailed exposition of current and emerging treatment modalities, spanning first-line interventions, a comprehensive array of second-line options, and novel therapeutic agents currently under investigation. Finally, the review addresses the crucial long-term management strategies, encompassing sustained monitoring, vital quality of life considerations, and the profound psychosocial impact of ITP on affected individuals and their families, thereby providing a holistic perspective on this challenging condition.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

1. Introduction

Immune Thrombocytopenia (ITP), historically recognized as Idiopathic Thrombocytopenic Purpura, represents a paradigm of autoimmune pathology characterized by an isolated reduction in platelet count (thrombocytopenia) without any identifiable underlying cause. Its designation was formally updated to ‘Immune Thrombocytopenia’ to more accurately reflect its autoimmune etiology and to remove the term ‘idiopathic,’ which implied an unknown origin, a notion largely dispelled by decades of research [1, 2]. The core pathogenesis of ITP revolves around a profound loss of immune tolerance, leading to the generation of autoantibodies predominantly targeting specific glycoproteins on the platelet surface. This immunological assault orchestrates a dual mechanism of thrombocytopenia: accelerated clearance and destruction of circulating platelets, primarily within the reticuloendothelial system, and, increasingly recognized, a concomitant impairment in the production of new platelets from bone marrow megakaryocytes [3].

ITP manifests across the lifespan, exhibiting two principal clinical forms: acute ITP, which predominantly affects children and often presents as a self-limiting condition following an infectious trigger; and chronic ITP, more commonly observed in adults, characterized by persistent thrombocytopenia lasting beyond 12 months, and often necessitating ongoing therapeutic intervention [4]. The clinical spectrum of ITP is highly variable, ranging from asymptomatic low platelet counts incidentally discovered to life-threatening hemorrhagic episodes. This detailed review aims to provide an exhaustive analysis of ITP, extending from its fundamental pathophysiological underpinnings and global epidemiological patterns to the complexities of its diagnosis, the evolving landscape of treatment strategies, and the critical aspects of long-term patient management, including its significant impact on patients’ quality of life and their families.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2. Pathophysiology

The pathophysiology of ITP is remarkably intricate, involving a complex interplay between humoral and cellular immune responses, genetic predispositions, and environmental triggers. The central tenet remains the breakdown of immunological self-tolerance, leading to the immune system mistakenly attacking its own platelets and megakaryocytes.

2.1 Autoantibody Formation and Platelet Destruction

The hallmark of ITP is the presence of autoantibodies directed against specific glycoproteins expressed on the surface of platelets. While anti-platelet autoantibodies are detectable in approximately 50-70% of ITP patients, their absence does not rule out the diagnosis, as other immune mechanisms contribute to the disease [5]. The primary targets of these autoantibodies are typically glycoprotein (GP) IIb/IIIa (integrin αIIbβ3) and GPIb/IX (glycocalicin), though antibodies against GPV and GPIa/IIa are also identified [6, 7]. These glycoproteins are crucial for platelet adhesion and aggregation, playing central roles in hemostasis. The autoantibodies, predominantly of the IgG class (IgG1 and IgG3 subclasses), facilitate platelet destruction through several distinct yet interconnected mechanisms:

• Opsonization and Phagocytosis: The most well-understood mechanism involves the binding of autoantibodies to platelet surface glycoproteins, effectively opsonizing them. These antibody-coated platelets are then recognized by Fc-gamma receptors (FcγRs), particularly FcγRI (CD64) and FcγRIII (CD16), expressed on the surface of macrophages and other phagocytic cells within the reticuloendothelial system. The spleen is the predominant site for this process due to its unique microvasculature, which allows for efficient interaction between antibody-coated platelets and resident macrophages. However, the liver, bone marrow, and other lymphoid tissues also contribute to platelet clearance, particularly in patients who have undergone splenectomy [8]. The binding of the Fc portion of the autoantibody to FcγRs triggers the engulfment and subsequent destruction of the platelets by the phagocytes.

• Complement Activation: In some cases, the binding of autoantibodies to platelets can activate the classical complement cascade. Autoantibodies, particularly those of the IgG1 and IgG3 subclasses, can bind C1q, initiating a cascade of proteolytic events that lead to the formation of the membrane attack complex (MAC) (C5b-9). MAC insertion into the platelet membrane results in osmotic lysis and direct destruction of platelets. Furthermore, complement activation can also lead to the deposition of complement components like C3b on the platelet surface, acting as additional opsonins that enhance phagocytosis by macrophages expressing complement receptors [9]. This mechanism, while less prominent than direct FcγR-mediated phagocytosis, contributes to the overall platelet destruction.

• Antibody-Dependent Cellular Cytotoxicity (ADCC): Beyond direct phagocytosis, autoantibody-coated platelets can also be targeted for destruction by natural killer (NK) cells. NK cells express FcγRIIIa (CD16) and can bind to the Fc portion of autoantibodies on the platelet surface, triggering their cytotoxic activity. This leads to the release of perforin and granzymes, inducing apoptosis in the targeted platelets [10].

2.2 T-Cell Mediated Mechanisms

While autoantibodies are central, emerging evidence increasingly highlights the critical role of T-cells in the pathogenesis of ITP, influencing both platelet destruction and impaired production. ITP is not solely a B-cell mediated disease; T-cell dysregulation is now recognized as fundamental to the loss of immune tolerance:

• Dysfunction of Regulatory T-cells (Tregs): Regulatory T-cells (CD4+CD25+FOXP3+) are crucial for maintaining immunological self-tolerance by suppressing autoreactive T-cell responses. In ITP, there is often a quantitative reduction or, more commonly, a functional impairment of Tregs [11]. This deficiency leads to inadequate suppression of autoreactive T-cells, allowing them to proliferate and differentiate, thus perpetuating the autoimmune response against platelets and megakaryocytes. Decreased expression of FoxP3 and reduced production of immunosuppressive cytokines like IL-10 and TGF-β by Tregs contribute to this imbalance.

• Activation of Helper T-cells: The T-helper (Th) cell subsets play distinct roles. An imbalance towards pro-inflammatory Th1 and Th17 responses is often observed. Th1 cells, through the production of interferon-gamma (IFN-γ), can promote macrophage activation and increase FcγR expression, thereby enhancing platelet destruction. Th17 cells, characterized by IL-17 production, contribute to inflammation and potentially recruit other immune cells to sites of platelet destruction. Conversely, there may be a relative deficiency or dysfunction of Th2 cells, which typically produce IL-4 and IL-13, cytokines associated with allergic responses and humoral immunity [12].

• Cytotoxic T-Lymphocytes (CTLs): Beyond their role in viral infections, CD8+ cytotoxic T-lymphocytes (CTLs) are implicated in directly mediating platelet and megakaryocyte destruction in ITP. These autoreactive CTLs can recognize platelet- or megakaryocyte-derived antigens presented on MHC class I molecules and directly induce apoptosis via perforin and granzyme pathways. This mechanism contributes significantly to both accelerated platelet destruction and impaired platelet production by targeting their precursors in the bone marrow [13].

2.3 Genetic Factors

Genetic predisposition plays a significant role in determining an individual’s susceptibility to ITP, although it is rarely the sole cause. A combination of specific gene polymorphisms can increase the risk, suggesting a multifactorial etiology where genetic background interacts with environmental triggers:

• Fc Receptor Genes (FCGR): Polymorphisms in genes encoding Fc-gamma receptors on phagocytes are consistently associated with ITP risk and response to treatment. For instance, single nucleotide polymorphisms (SNPs) in FCGR2A (H131R) and FCGR3A (V158F) can alter the affinity of these receptors for IgG, thereby influencing the efficiency of platelet opsonization and clearance. The low-affinity variants may be protective, while high-affinity variants could increase susceptibility [14].

• Human Leukocyte Antigen (HLA) Alleles: Certain HLA alleles, particularly those within the class II region (e.g., HLA-DRB1, DQB1), are associated with ITP susceptibility, suggesting a role in antigen presentation and T-cell activation. The specific HLA haplotype varies geographically [15].

• Cytokine Genes: Polymorphisms in genes encoding pro-inflammatory cytokines such as TNF-α, IL-10, and IFN-γ have been linked to ITP, potentially influencing the immune response’s magnitude and duration [16].

• Immune Checkpoint Molecules: Genes related to immune regulation, such as CTLA-4 (Cytotoxic T-Lymphocyte-Associated protein 4) and PTPN22 (Protein Tyrosine Phosphatase Non-Receptor Type 22), are associated with various autoimmune diseases, including ITP. Polymorphisms in these genes can impair the negative regulation of immune responses, leading to chronic activation of autoreactive lymphocytes [17].

• Killer Cell Immunoglobulin-like Receptors (KIR): Genes encoding KIRs on NK cells, which interact with HLA class I molecules, are also implicated. Specific KIR/HLA combinations can affect NK cell activity, influencing ADCC and overall immune regulation.

These genetic factors alone are typically insufficient to cause the disease, emphasizing the necessity of environmental triggers to initiate the autoimmune cascade in genetically predisposed individuals.

2.4 Role of the Spleen

The spleen plays a pivotal and multifaceted role in ITP pathogenesis, acting as both a primary site of platelet destruction and a significant center for autoantibody production. Its unique anatomical structure and immunological functions make it central to the disease:

• Primary Site of Platelet Destruction: The splenic red pulp is rich in macrophages expressing high levels of FcγRs. Its distinctive microcirculation, characterized by slow blood flow and narrow vascular channels, facilitates prolonged contact between antibody-coated platelets and these resident macrophages. This optimal environment leads to the efficient recognition, engulfing, and destruction of opsonized platelets [18].

• Site of Autoantibody Production: The white pulp of the spleen is a major lymphoid organ where B-cells differentiate into plasma cells and produce autoantibodies against platelet surface antigens. It is believed that autoreactive B-cells are activated and proliferate within the spleen, contributing significantly to the systemic autoantibody load [19].

Given these dual roles, splenectomy, the surgical removal of the spleen, has historically been a highly effective treatment for chronic ITP, particularly in patients unresponsive to initial medical therapies. By removing the primary organ responsible for both platelet clearance and a substantial portion of autoantibody production, splenectomy can lead to sustained remission in a significant proportion of patients.

2.5 Role of Environmental Factors

Environmental factors often serve as triggers for ITP, particularly in genetically susceptible individuals, by initiating or exacerbating the breakdown of immune tolerance:

• Infections: Viral infections are frequently implicated, especially in childhood acute ITP. Common culprits include Epstein-Barr Virus (EBV), Cytomegalovirus (CMV), Varicella-Zoster Virus (chickenpox), Rubella, Human Immunodeficiency Virus (HIV), and Hepatitis C Virus (HCV) [20]. The mechanisms include molecular mimicry (viral antigens resembling platelet glycoproteins), polyclonal B-cell activation, or immune dysregulation following viral clearance. Helicobacter pylori infection has also been strongly associated with chronic ITP in adults, with eradication leading to platelet count improvement in a subset of patients [21].

• Medications: Drug-induced immune thrombocytopenia (DITP) is a recognized phenomenon where certain drugs can trigger an immune response against platelets. Examples include quinine, quinidine, heparin (heparin-induced thrombocytopenia, HIT), certain antibiotics (e.g., sulfonamides, vancomycin), gold salts, and some anticonvulsants. The drug can act as a hapten, forming complexes with platelet surface proteins, thereby eliciting an antibody response [22].

• Vaccinations: While rare, some vaccinations, particularly the Measles, Mumps, and Rubella (MMR) vaccine, have been associated with transient thrombocytopenia in children, typically resolving spontaneously. More recently, cases of ITP have been reported following COVID-19 vaccination, though the incidence is extremely low and the benefits of vaccination far outweigh this minimal risk [23].

• Other Environmental Exposures: Less commonly, exposure to certain toxins or chemicals has been anecdotally linked, though large-scale evidence is limited.

The interplay between these environmental factors and the genetic predisposition, along with existing immune dysregulation, collectively contributes to the initiation and perpetuation of ITP.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3. Epidemiology

ITP is considered a rare disease, yet it is the most common cause of isolated thrombocytopenia across all age groups. Its epidemiology presents distinct patterns based on age, gender, and geographical distribution.

The global incidence of ITP is estimated to range from 50 to 100 individuals per million annually. However, there is significant variability depending on the population studied and the diagnostic criteria applied. The disease exhibits a characteristic bimodal age distribution, with two distinct peaks:

• First Peak: Early Childhood: A prominent peak occurs in children, typically between 2 and 6 years of age. Childhood ITP often follows an acute, self-limiting course, with spontaneous remission occurring in over 80% of cases within six months [24]. The incidence in children is approximately 1.9 to 6.4 cases per 100,000 children per year.

• Second Peak: Adulthood (Elderly): A second, broader peak is observed in adults, particularly those aged 50-60 years and older. In this age group, ITP is more likely to pursue a chronic course, with spontaneous remission being less common compared to children. The incidence in adults is around 2.2 to 5.3 cases per 100,000 adults per year [25].

Gender Distribution: In children, there is a slight male predominance for acute ITP. However, in adults, chronic ITP tends to affect females more frequently than males, particularly in younger adult years (e.g., 20-40 years), with the ratio becoming more balanced or even reversed in older age groups (>60 years) [26].

Prevalence: The estimated prevalence of ITP, defined as the number of individuals living with the condition, varies significantly. For chronic ITP, particularly in adults, estimates range from 9.5 to 26 per 100,000 individuals, reflecting the long-term nature of the disease in many cases [27].

Geographical and Racial Variations: Epidemiological data suggest some geographical variation in incidence, potentially linked to differences in healthcare access, diagnostic practices, and prevalence of associated infections (e.g., H. pylori). While ITP affects all races and ethnicities, studies have occasionally noted slight differences in prevalence or disease characteristics among different racial groups, although comprehensive data are still limited.

Associated Conditions and Comorbidities: ITP can exist as a primary, isolated condition, but it is also associated with a variety of other autoimmune disorders, underscoring the systemic nature of immune dysregulation. These include systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), rheumatoid arthritis, autoimmune thyroid disease (Hashimoto’s thyroiditis, Graves’ disease), and Sjögren’s syndrome [28]. Additionally, chronic infections such as HIV, HCV, and H. pylori are well-known associations. The presence of these comorbidities can complicate diagnosis and management, often influencing treatment choices and overall prognosis. Furthermore, patients with ITP, especially those on long-term treatments like corticosteroids or post-splenectomy, are at an increased risk of infections and thrombotic events, which contribute to the overall burden of the disease and impact patient outcomes [29].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4. Diagnostic Challenges

The diagnosis of ITP is primarily one of exclusion, meaning that clinicians must meticulously rule out all other potential causes of isolated thrombocytopenia before establishing a diagnosis of primary ITP. This approach is critical to avoid misdiagnosis and inappropriate treatment, given the broad differential diagnosis for low platelet counts.

4.1 Exclusion of Secondary Causes

An exhaustive clinical evaluation is paramount to identify or exclude secondary causes of thrombocytopenia. The differential diagnosis is extensive and includes, but is not limited to, the following categories:

• Medication-Induced Thrombocytopenia: A thorough medication history is essential. Numerous drugs can induce thrombocytopenia through various mechanisms, including immune-mediated destruction (e.g., quinine, quinidine, certain antibiotics like trimethoprim-sulfamethoxazole, vancomycin, linezolid, anti-epileptics) or direct bone marrow suppression (e.g., chemotherapy agents, certain anti-cancer drugs). Heparin-induced thrombocytopenia (HIT) is a particularly important and distinct entity, characterized by thrombotic complications rather than bleeding [22].

• Infections: Various infectious agents can lead to thrombocytopenia. Viral infections such as HIV, Hepatitis C Virus (HCV), Epstein-Barr Virus (EBV), Cytomegalovirus (CMV), and Human Herpesvirus 6 (HHV-6) can directly suppress bone marrow, cause immune-mediated destruction, or lead to disseminated intravascular coagulation (DIC). Bacterial sepsis can also cause thrombocytopenia through bone marrow suppression or consumption. Helicobacter pylori infection, while often asymptomatic, has a recognized association with chronic ITP and should be screened for [21].

• Systemic Autoimmune Disorders: Thrombocytopenia can be a feature of other systemic autoimmune diseases, often preceding or co-occurring with other classic manifestations. These include Systemic Lupus Erythematosus (SLE), Antiphospholipid Syndrome (APS), Rheumatoid Arthritis, Sjögren’s Syndrome, and autoimmune thyroid diseases [28]. Appropriate serological testing (e.g., ANA, anti-dsDNA, antiphospholipid antibodies, thyroid function tests) is crucial in these cases.

• Malignancies: Malignant conditions, particularly hematological malignancies such as acute leukemias, lymphomas, and myelodysplastic syndromes (MDS), can cause thrombocytopenia due to bone marrow infiltration, chemotherapy effects, or associated immune phenomena (paraneoplastic syndromes). Solid tumors with bone marrow metastases can also present with low platelet counts.

• Other Hematologic Disorders: A range of other primary hematologic conditions must be excluded. These include:

  • Thrombotic Microangiopathies (TMAs): Thrombotic Thrombocytopenic Purpura (TTP) and Hemolytic Uremic Syndrome (HUS) are characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ damage, requiring urgent specific treatment. Differentiation from ITP is critical as TTP treatment involves plasma exchange, which is contraindicated in ITP. Evaluation for schistocytes on peripheral smear and ADAMTS13 activity is key [30].
  • Aplastic Anemia: Characterized by pancytopenia (low counts of all blood cell lines) due to bone marrow failure.
  • Myelodysplastic Syndromes (MDS): Clonal hematopoietic stem cell disorders that often present with cytopenias, including thrombocytopenia, along with dysplastic features in the bone marrow.
  • Congenital Thrombocytopenias: Rare inherited disorders causing low platelet counts, often identifiable by family history, specific platelet morphology, or genetic testing (e.g., Bernard-Soulier syndrome, May-Hegglin anomaly, Wiskott-Aldrich syndrome).
  • Hypersplenism: Enlarged spleen from various causes (e.g., portal hypertension, liver cirrhosis, chronic infections) leading to sequestration and destruction of platelets.
  • Nutritional Deficiencies: Severe deficiencies of Vitamin B12 or Folate can lead to impaired hematopoiesis and pancytopenia, including thrombocytopenia.

• Pseudothrombocytopenia: An artifactual low platelet count due to in vitro platelet clumping, often caused by EDTA anticoagulant in blood collection tubes. This is a common pitfall and can be readily identified by examining a peripheral blood smear for platelet aggregates or by repeating the platelet count using a citrate or heparin tube [31].

4.2 Laboratory Investigations

Once secondary causes are clinically considered, laboratory investigations play a crucial role in supporting the diagnosis of ITP and ruling out mimics:

• Complete Blood Count (CBC) with Differential: The cornerstone of diagnosis. ITP is characterized by isolated thrombocytopenia, meaning the hemoglobin and white blood cell counts (including differential) are typically within normal limits. Any significant abnormalities in other cell lines should prompt suspicion of an alternative diagnosis [3].

• Peripheral Blood Smear Examination: This is perhaps the most important initial laboratory test. A careful manual review of the blood smear is essential to:

  • Confirm true thrombocytopenia and exclude pseudothrombocytopenia (by observing the absence of platelet clumping).
  • Assess platelet morphology: In ITP, platelets are often larger than normal (megathrombocytes or ‘giant platelets’), which is an indicator of active, compensatory platelet production by the bone marrow in response to peripheral destruction. Normal platelet morphology can also be seen.
  • Exclude other causes: The absence of schistocytes (fragmented red blood cells) is crucial to differentiate ITP from thrombotic microangiopathies (TTP/HUS). Absence of abnormal cells (blasts) or dysplastic features in other cell lines (e.g., oval macrocytes, hypersegmented neutrophils) helps rule out leukemia, MDS, or nutritional deficiencies [32].

• Bone Marrow Examination: While not routinely required for typical ITP presentations, a bone marrow biopsy and aspirate are indicated in specific circumstances to exclude underlying conditions and assess megakaryocyte status:

  • Patients over 60 years of age, due to increased risk of MDS or lymphoproliferative disorders.
  • Atypical blood count findings (e.g., anemia, leukopenia, or abnormal cell morphology on peripheral smear).
  • Failure to respond to first-line therapies, suggesting a possible alternative diagnosis or refractory disease.
  • Prior to splenectomy, to confirm adequate megakaryocyte numbers [33].
  • Typical findings in ITP are normal or, more commonly, an increased number of megakaryocytes that may appear immature or show morphological abnormalities, reflecting the bone marrow’s attempt to compensate for accelerated platelet destruction.

• Anti-platelet Antibody Testing: Detection of anti-platelet autoantibodies (e.g., anti-GPIIb/IIIa, anti-GPIb/IXa) can provide supportive evidence for ITP but is not definitive. These tests include enzyme-linked immunosorbent assays (ELISA) and monoclonal antibody-specific immobilization of platelet antigens (MAIPA) assays. The sensitivity and specificity vary, and a significant proportion of ITP patients (up to 30-50%) may test negative, particularly due to technical limitations or because the antibodies are bound to platelets and not freely circulating. Conversely, positive tests can occur in other conditions. Therefore, these tests are generally not used for primary diagnosis but rather as an adjunctive tool in uncertain cases [5].

• Tests to Exclude Secondary Causes: Based on clinical suspicion, further tests may be necessary: HIV and HCV serologies, H. pylori stool antigen or urea breath test, antinuclear antibodies (ANA), anti-dsDNA, antiphospholipid antibodies, thyroid function tests, liver and renal function tests, Coombs’ test (to exclude autoimmune hemolytic anemia, often co-occurring with ITP in Evans Syndrome), Vitamin B12 and folate levels, and ADAMTS13 activity (for TTP).

4.3 Clinical Assessment

A thorough clinical history and physical examination are indispensable in the diagnostic process of ITP, providing crucial clues and guiding subsequent investigations:

• Detailed Medical History:

  • Bleeding Symptoms: The nature, severity, onset, and duration of bleeding symptoms are paramount. Typical mucocutaneous bleeding includes petechiae (small, pinpoint red spots), purpura (larger bruises), ecchymoses (extensive bruising), epistaxis (nosebleeds), gingival bleeding, and menorrhagia (heavy menstrual bleeding). More severe bleeding, though less common, can involve gastrointestinal hemorrhage, hematuria, or, rarely, intracranial hemorrhage (ICH), which is the most feared complication [34].
  • Medication History: As previously noted, a comprehensive review of all current and recent medications, including over-the-counter drugs, herbal supplements, and illicit drugs, is critical.
  • Infection History: Recent viral or bacterial infections, particularly in children (e.g., upper respiratory infections, childhood exanthems) or a history of chronic infections (HIV, HCV).
  • Past Medical History: Presence of other autoimmune disorders, malignancy, liver disease, kidney disease, or prior transfusion reactions.
  • Family History: While most ITP is sporadic, a family history of autoimmune disorders or congenital thrombocytopenias should be explored.
  • Lifestyle Factors: Alcohol consumption, nutritional status.

• Physical Examination:

  • Assessment of Bleeding: Observe the skin and mucous membranes for evidence of petechiae, purpura, ecchymoses, or active bleeding. The distribution and size of these lesions can provide insights into bleeding severity.
  • Splenomegaly and Lymphadenopathy: In primary ITP, the spleen is typically not enlarged. The presence of significant splenomegaly or generalized lymphadenopathy should raise suspicion for secondary causes such as lymphoma, leukemia, or systemic infections. If present, splenomegaly could indicate hypersplenism [3].
  • Signs of Other Autoimmune Diseases: Look for signs of systemic lupus erythematosus (e.g., malar rash, joint swelling), thyroid disease (e.g., goiter), or liver disease (e.g., jaundice, stigmata of chronic liver disease).

• Severity Grading: Clinical assessment of bleeding severity is crucial for guiding treatment decisions. Several grading systems exist, such as the ITP-BAT (ITP Bleeding Assessment Tool) or the WHO bleeding scale, which help standardize the assessment of mucocutaneous and visceral bleeding [35]. Platelet count alone does not always correlate with bleeding risk, as some patients with very low platelet counts remain asymptomatic, while others with relatively higher counts may experience significant bleeding.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5. Natural Course of the Disease

The natural course of ITP varies considerably depending on the age of onset, defining distinct clinical trajectories for acute (primarily childhood) and chronic (primarily adult) forms of the disease. This variability dictates different management approaches and prognoses.

5.1 Acute ITP (Children)

Acute ITP is the predominant form observed in children, most commonly affecting those between 2 and 6 years of age. Its onset is typically abrupt and often follows a common viral infection (e.g., upper respiratory infection, chickenpox, measles, mumps) by 1 to 4 weeks, suggesting an infectious trigger for the autoimmune response [24].

• Clinical Presentation: Children often present with sudden onset of purpura, petechiae, and bruising, primarily on the skin and mucous membranes. Epistaxis and gingival bleeding are also common. Despite often very low platelet counts (frequently <10 x 10^9/L), severe or life-threatening bleeding, particularly intracranial hemorrhage (ICH), is remarkably rare, occurring in less than 1% of cases [36]. This phenomenon, where clinical bleeding severity does not directly correlate with platelet count, is a characteristic feature of ITP, likely due to the presence of larger, more functionally active platelets or other compensatory hemostatic mechanisms.

• Prognosis and Remission: The hallmark of acute childhood ITP is its self-limited nature. Spontaneous remission, defined as a sustained platelet count above 150 x 10^9/L without therapy, occurs in approximately 80% of children within six months of diagnosis [24]. The majority of these remissions happen within the first few weeks to months. Treatment in acute childhood ITP is often aimed at preventing significant bleeding during the acute phase rather than achieving a permanent cure, given the high rate of spontaneous recovery. Observational management may be appropriate for children with mild or no bleeding, even with very low platelet counts.

• Factors Predicting Chronicity: While most children achieve remission, about 20% will progress to chronic ITP. Factors associated with an increased risk of chronicity include older age at presentation (e.g., school-aged children and adolescents), an insidious onset without a clear preceding infection, and lack of initial response to corticosteroids or IVIg [37].

5.2 Chronic ITP (Adults)

Chronic ITP is significantly more prevalent in adults and is defined as thrombocytopenia persisting for more than 12 months from diagnosis, irrespective of treatment [38]. While the previous definition used 6 months, the current international consensus considers 12 months to better differentiate it from resolving acute phases.

• Clinical Presentation: The onset in adults is often insidious, with symptoms developing gradually over weeks or months. Bleeding manifestations are similar to those in children but can vary widely in severity. Some adults may present with incidentally discovered low platelet counts and no significant bleeding, while others experience recurrent or persistent mucocutaneous bleeding that significantly impacts their daily lives. Life-threatening bleeding, including ICH, remains rare but is a persistent concern, particularly with very low platelet counts (<10-20 x 10^9/L) or in the context of additional risk factors (e.g., hypertension, anticoagulant use, advanced age) [34].

• Disease Course and Prognosis: Unlike childhood ITP, spontaneous remission is uncommon in adult chronic ITP, occurring in only about 5-10% of patients. The disease course is highly variable, often characterized by fluctuating platelet counts, with periods of remission and relapse, or sustained low counts requiring ongoing treatment. Chronic ITP typically requires therapeutic intervention to maintain safe platelet counts and prevent bleeding [39].

• Impact on Quality of Life (QoL): Chronic ITP can profoundly impact patients’ quality of life. Beyond the direct effects of bleeding and the fear of severe hemorrhage, patients frequently experience debilitating fatigue, which is often disproportionate to their platelet count or anemia status. Anxiety and depression are also common, stemming from the unpredictable nature of the disease, the need for frequent monitoring, the side effects of treatments, and limitations on daily activities. This psychosocial burden often requires comprehensive supportive care and psychological interventions [40].

• Comorbidities: Adults with chronic ITP may develop comorbidities not directly related to the disease itself but often exacerbated by its management. Long-term corticosteroid use is associated with osteoporosis, diabetes mellitus, hypertension, cataracts, and increased susceptibility to infections. Patients, particularly those who have undergone splenectomy, also face an increased long-term risk of severe infections (overwhelming post-splenectomy infection, OPSI) and thrombotic events [29].

• Refractory ITP: A subset of patients with chronic ITP will be designated as having refractory ITP, defined as failure to respond adequately to at least two lines of treatment, including corticosteroids and splenectomy (or for whom splenectomy is contraindicated). These patients represent a significant therapeutic challenge and often require multiple lines of therapy to achieve and maintain safe platelet counts [38].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6. Treatment Approaches

The primary goal of ITP treatment is not necessarily to normalize the platelet count but rather to achieve a safe platelet count (typically >30-50 x 10^9/L) sufficient to prevent clinically significant bleeding, especially severe or life-threatening hemorrhage [38]. Treatment decisions are highly individualized, taking into account the patient’s age, platelet count, presence and severity of bleeding symptoms, associated comorbidities, quality of life, and personal preferences. Observation without treatment is appropriate for many patients, particularly children with mild or no bleeding and adults with platelet counts >30 x 10^9/L and no significant bleeding.

6.1 First-Line Therapies

These are typically the initial treatments employed for patients requiring intervention due to low platelet counts with significant bleeding or high risk of bleeding.

• Corticosteroids:

  • Mechanism of Action: Corticosteroids (e.g., prednisone, dexamethasone) are highly effective in ITP through multiple mechanisms. They suppress autoantibody production by inhibiting B-cell and T-cell activity, reduce the affinity of Fc receptors on macrophages, thereby decreasing platelet destruction, and directly strengthen capillary integrity, reducing bleeding even before platelet counts rise [41].
  • Dosing and Efficacy:
    • Prednisone: Typically administered orally at 1 mg/kg/day (up to 60-100 mg/day) for 2-4 weeks, followed by a gradual taper. Response rates are high, with 70-80% of patients achieving an initial platelet response (>30 x 10^9/L). However, sustained remission after tapering is achieved in only about 20-30% of adults, indicating a high relapse rate upon discontinuation or dose reduction.
    • Dexamethasone: High-dose dexamethasone (HDD) regimens (e.g., 40 mg daily for 4 consecutive days, repeated up to 3-4 cycles) offer a more intensive, pulse-dose approach. This regimen can induce faster and potentially more durable responses than prednisone in some patients, with response rates similar to or slightly higher than prednisone (around 70-80% initial response), but also with varying rates of sustained remission [42].
  • Side Effects: The major limitation of corticosteroids is their extensive side effect profile, especially with prolonged use. These include weight gain, fluid retention, hyperglycemia (diabetes), hypertension, osteoporosis, mood disturbances (insomnia, anxiety, depression), increased susceptibility to infections, gastric irritation/ulcers, cataracts, glaucoma, and Cushingoid features. Due to these adverse effects, long-term corticosteroid use is generally discouraged, and steroid-sparing strategies are often pursued if prolonged treatment is required.

• Intravenous Immunoglobulin (IVIg):

  • Mechanism of Action: IVIg provides rapid, temporary increases in platelet counts, making it ideal for acute, severe bleeding or pre-surgical preparation. Its mechanisms are multifaceted, including saturation of Fc receptors on macrophages, thus blocking the uptake of autoantibody-coated platelets; modulation of autoantibody production; interference with complement activation; and anti-idiotypic antibody effects that neutralize autoantibodies [43].
  • Dosing and Efficacy: The typical dose is 0.8-1 g/kg (often given as a single infusion or divided over 2 days). Platelet counts usually rise within 24-48 hours. Initial response rates are very high (80-90%), but the effect is transient, typically lasting only 2-4 weeks due to the half-life of IgG. IVIg does not induce long-term remission but serves as an effective bridge therapy or emergency treatment.
  • Side Effects: Common side effects include headache (often severe, sterile aseptic meningitis can occur), fever, chills, nausea, myalgia, and fatigue. More serious but rare adverse events include renal dysfunction (especially with older preparations in vulnerable patients), thrombotic events (due to increased blood viscosity), and anaphylaxis (in patients with IgA deficiency). Pre-hydration and slow infusion rates can mitigate some side effects.

6.2 Second-Line Therapies

When first-line therapies fail to achieve a durable and safe platelet count, or when corticosteroid side effects become prohibitive, second-line treatments are considered. The choice of second-line therapy depends on multiple factors, including efficacy, safety profile, patient comorbidities, and patient preference.

• Thrombopoietin Receptor Agonists (TPO-RAs):

  • Mechanism of Action: TPO-RAs mimic the action of endogenous thrombopoietin, the primary regulator of megakaryopoiesis. They bind to and activate the thrombopoietin receptor (TPO-R or c-Mpl) on megakaryocytes and hematopoietic stem cells, stimulating megakaryocyte proliferation, differentiation, and subsequent platelet production in the bone marrow [44]. This addresses the impaired platelet production component of ITP pathophysiology.
  • Agents: Currently, three TPO-RAs are approved for ITP:
    • Romiplostim (Nplate®): A peptide-mimetic TPO-RA administered weekly by subcutaneous injection. It offers the advantage of non-oral administration, which may improve adherence in some patients. Response rates are approximately 70-80%, with a significant proportion achieving stable, durable responses.
    • Eltrombopag (Promacta®/Revolade®): A small-molecule, non-peptide TPO-RA administered orally once daily. It requires specific dietary restrictions (avoiding dairy products, calcium-rich foods, and antacids within 4 hours of dosing) due to chelation with polyvalent cations, which can impair absorption. Response rates are similar to romiplostim.
    • Avatrombopag (Doptelet®): A newer oral TPO-RA with minimal dietary restrictions, offering greater flexibility in administration. Approved for chronic ITP in adults who have had an insufficient response to previous treatment [45].
  • Side Effects: Common side effects include headache, fatigue, nausea, and musculoskeletal pain. More significant concerns include:
    • Rebound Thrombocytopenia: Upon discontinuation, platelet counts can drop below baseline levels, necessitating careful tapering or bridging to other therapies.
    • Thrombotic Events: Increased risk of venous and arterial thrombotic events, particularly in elderly patients or those with pre-existing risk factors. This is thought to be due to sustained high platelet counts or direct effects of the drugs on coagulation pathways [46].
    • Bone Marrow Reticulin Fibrosis: A theoretical concern due to chronic marrow stimulation, requiring regular monitoring of peripheral blood smear for abnormal cells and occasional bone marrow biopsies. Clinically significant fibrosis or progression to myelodysplastic syndrome/leukemia is rare.
    • Hepatotoxicity: Eltrombopag requires monitoring of liver enzymes due to potential hepatotoxicity.

• Rituximab:

  • Mechanism of Action: Rituximab is a chimeric monoclonal antibody that selectively targets the CD20 antigen expressed on the surface of pre-B and mature B lymphocytes, leading to their depletion through various mechanisms (e.g., ADCC, complement-dependent cytotoxicity, apoptosis). By depleting B-cells, rituximab reduces the production of platelet-specific autoantibodies [47].
  • Dosing and Efficacy: Typically administered intravenously at 375 mg/m² weekly for 4 doses, or a lower fixed dose (e.g., 100 mg weekly for 4 doses) has shown similar efficacy with reduced side effects. Response rates vary, with overall response around 40-60%, but durable complete responses are achieved in a smaller proportion (15-20%). The platelet response can be delayed, sometimes taking several months.
  • Side Effects: Infusion-related reactions (fever, chills, rash, hypotension) are common, especially with the first infusion, and can be mitigated by premedication. Increased risk of infections (particularly viral infections like progressive multifocal leukoencephalopathy, PML, though very rare in ITP settings) is a significant concern. Reactivation of Hepatitis B virus also requires screening and prophylactic antiviral therapy.

• Splenectomy:

  • Mechanism of Action: Surgical removal of the spleen fundamentally alters the disease course by eliminating the primary site of autoantibody-mediated platelet destruction and a major site of autoantibody production. This directly reduces platelet clearance and the overall autoimmune attack [18].
  • Indications: Considered a highly effective second-line therapy for chronic ITP patients who are refractory to first-line medical treatments or who cannot tolerate them, and who require durable remission. It is generally reserved for patients with severe, persistent thrombocytopenia and significant bleeding risk after other options have failed.
  • Efficacy: Splenectomy provides durable responses in about two-thirds of patients, making it one of the most effective long-term treatments for chronic ITP [48].
  • Pre-splenectomy Workup: Crucial preparation includes vaccination against encapsulated bacteria (pneumococcus, Haemophilus influenzae type B, meningococcus) several weeks before surgery to reduce the risk of overwhelming post-splenectomy infection (OPSI). Eradication of H. pylori should also be considered if positive.
  • Risks and Complications:
    • Immediate Surgical Risks: Bleeding, infection, pancreatitis, damage to adjacent organs, and thrombotic events (portal vein thrombosis being a rare but serious complication).
    • Long-term Risks: The most significant long-term risk is OPSI, a life-threatening fulminant infection with encapsulated bacteria (e.g., Streptococcus pneumoniae). Patients require lifelong vigilance and potentially prophylactic antibiotics. There is also an increased long-term risk of thrombotic events (both arterial and venous) post-splenectomy, which may necessitate anti-platelet or anticoagulant therapy in selected patients [29].

• Fostamatinib (Tavlesse®/Rigel):

  • Mechanism of Action: Fostamatinib is an oral small-molecule inhibitor of spleen tyrosine kinase (Syk). Syk is a crucial intracellular signaling molecule in various immune cells, including macrophages, B-cells, and mast cells. By inhibiting Syk, fostamatinib interferes with FcγR-mediated signaling, thereby reducing the phagocytic destruction of antibody-coated platelets by macrophages [49]. It specifically targets the destruction pathway rather than production.
  • Dosing and Efficacy: Administered orally twice daily. Approved for chronic ITP in adults who have had an insufficient response to previous treatment. Clinical trials show response rates of around 40-50%, with some patients achieving durable increases in platelet counts.
  • Side Effects: Common side effects include diarrhea, hypertension, nausea, and transaminase elevations. These are generally manageable but may require dose adjustments or discontinuation.

• Immunosuppressants (Older/Less Common Second-Line):

  • These agents are typically used in refractory cases or as steroid-sparing agents, but their use has diminished with the advent of TPO-RAs and rituximab due to higher toxicity and slower onset of action.
  • Azathioprine: A purine analog that inhibits lymphocyte proliferation. Used orally. Side effects include myelosuppression, hepatotoxicity, and increased infection risk.
  • Mycophenolate Mofetil (MMF): Inhibits purine synthesis, primarily affecting lymphocyte proliferation. Used orally. Side effects include gastrointestinal upset, myelosuppression, and increased infection risk.
  • Cyclosporine/Tacrolimus: Calcineurin inhibitors that suppress T-cell activation. Side effects include nephrotoxicity, hypertension, and neurotoxicity.
  • Cyclophosphamide: An alkylating agent with broad immunosuppressive effects. Reserved for severe, highly refractory cases due to significant toxicity, including myelosuppression, hemorrhagic cystitis, and increased risk of secondary malignancies.

6.3 Emerging Therapies and Other Treatments

The landscape of ITP treatment is continually evolving, with numerous novel agents targeting different pathophysiological pathways. These therapies hold promise for patients who are refractory to current options or for those seeking alternative treatment mechanisms.

• Bruton’s Tyrosine Kinase (BTK) Inhibitors: BTK is a key enzyme in B-cell receptor signaling, crucial for B-cell development, survival, and activation. Inhibiting BTK can suppress B-cell activity and potentially reduce autoantibody production. Oral BTK inhibitors like rilzabrutinib and fenebrutinib are in advanced clinical trials for ITP, showing promising results in increasing platelet counts with generally tolerable safety profiles [50].

• Neonatal Fc Receptor (FcRn) Inhibitors: The neonatal Fc receptor (FcRn) is responsible for protecting IgG antibodies from lysosomal degradation, thereby prolonging their half-life. By blocking FcRn, these inhibitors (e.g., efgartigimod, rozanolixizumab) accelerate the degradation of circulating IgG, including pathogenic autoantibodies, thereby reducing their levels and mitigating immune-mediated destruction [51]. These subcutaneous therapies are showing significant efficacy in clinical trials and are poised to become important therapeutic options.

• Other Syk Inhibitors: Beyond fostamatinib, other Syk inhibitors are under investigation, aiming for improved efficacy or safety profiles.

• Complement Inhibitors: Therapies targeting specific components of the complement cascade are being explored to block complement-mediated platelet destruction, particularly in patients where this pathway is highly active.

• Immunomodulatory Agents: Further research into agents that modulate T-cell function or cytokine balance continues. For instance, low-dose dapsone is used in some refractory cases, although its mechanism in ITP is not fully understood.

• Gene Therapy and Cellular Therapies: Highly experimental approaches are exploring gene therapy to correct immune dysregulation (e.g., engineered Tregs) or cell-based therapies, but these are currently far from clinical application.

• Supportive Therapies:

  • Platelet Transfusions: Generally reserved for life-threatening bleeding or as a prophylactic measure immediately prior to urgent surgical procedures. Platelets are rapidly destroyed in ITP, so transfusions often provide only a transient benefit and are not a primary treatment for ITP itself [38].
  • Antifibrinolytic Agents: Tranexamic acid or aminocaproic acid can be used to control mucocutaneous bleeding (e.g., epistaxis, menorrhagia) by stabilizing clots, regardless of platelet count. They are particularly useful as adjunctive therapies or for mild bleeding [52].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

7. Long-Term Management Strategies

Managing chronic ITP extends far beyond achieving platelet count targets; it encompasses comprehensive strategies to maintain stable hematological parameters, minimize treatment-related side effects, and, crucially, address the significant impact of the disease on patients’ quality of life and overall well-being.

7.1 Monitoring and Follow-Up

Regular and systematic monitoring is essential for all patients with ITP, regardless of their treatment status. The frequency of monitoring depends on disease activity, platelet count stability, and the specific treatment regimen.

• Platelet Counts and CBC: Regular complete blood counts are crucial to track platelet trends, assess treatment response, and detect any new cytopenias that might suggest an evolving myelodysplastic syndrome or other hematologic disorders. In stable patients, monitoring may be infrequent (e.g., every few months), while during treatment initiation or dose adjustments, weekly or bi-weekly monitoring may be necessary.

• Assessment for Bleeding Symptoms: Ongoing assessment for bleeding symptoms (e.g., petechiae, purpura, epistaxis, menorrhagia) is vital. Patients should be educated on recognizing signs of severe bleeding and when to seek urgent medical attention.

• Monitoring for Treatment-Related Side Effects:

  • Corticosteroids: Regular monitoring for osteoporosis (bone density scans), diabetes (HbA1c, fasting glucose), hypertension, and cataracts (ophthalmological exams) is crucial for patients on long-term or intermittent steroid therapy.
  • TPO-RAs: Monitoring for thrombotic events, particularly in high-risk patients, liver function tests (for eltrombopag), and peripheral blood smear/bone marrow assessment for reticulin fibrosis (periodically) are important [46].
  • Rituximab: Monitoring for infection risk, particularly viral infections, is important. Hepatitis B serology should be routinely checked before initiation.
  • Splenectomy: Lifelong monitoring for signs of infection (fever, chills) and education on urgent medical attention for such symptoms are paramount. Regular review of vaccination status and considering prophylactic antibiotics in specific high-risk situations are also important.

• Comorbidity Management: Proactive management of associated comorbidities (e.g., autoimmune conditions, H. pylori infection) is integral to optimizing ITP control and overall patient health.

7.2 Quality of Life Considerations

The profound impact of chronic ITP on a patient’s quality of life (QoL) is increasingly recognized as a critical outcome measure, often as important as platelet count control. Patients frequently grapple with symptoms and anxieties that significantly diminish their daily functioning and emotional well-being.

• Fatigue: Fatigue is a pervasive and debilitating symptom in ITP patients, often disproportionate to platelet counts or anemia levels. It can severely impact work, social activities, and overall energy levels. Management strategies include addressing potential contributing factors (e.g., anemia, thyroid dysfunction), promoting healthy sleep hygiene, regular moderate exercise, and providing psychological support [40].

• Anxiety and Depression: The unpredictable nature of ITP, the fear of bleeding, the burden of frequent medical appointments, and the side effects of treatments can lead to significant anxiety and depression. Screening for these mental health issues is important, and patients should be offered access to psychological counseling, cognitive behavioral therapy (CBT), and, if appropriate, pharmacotherapy.

• Impact on Daily Activities and Lifestyles: Patients may feel restricted in their activities (e.g., avoiding contact sports, fearing travel) due to the risk of bleeding or fear of complications. Education about safe activities, self-management strategies for minor bleeding, and promoting a sense of control can help alleviate these limitations.

• Steroid-Related QoL Impairment: The aesthetic changes (e.g., moon face, weight gain) and psychological side effects (e.g., mood swings, insomnia) of corticosteroids can be highly distressing and contribute significantly to QoL impairment, often motivating patients to seek steroid-sparing alternatives.

7.3 Impact on Patients and Families

ITP is a family disease. The unpredictability of bleeding episodes and the ongoing nature of chronic ITP can cause significant stress not only for the patient but also for their caregivers and family members. This shared burden necessitates a holistic approach to care.

• Emotional Burden: Families often experience worry and fear regarding bleeding complications, particularly intracranial hemorrhage in children. Parents of children with ITP may face significant distress and disruption to daily routines. Spouses and partners of adults with chronic ITP may take on increased caregiving responsibilities.

• Education and Empowerment: Comprehensive patient and family education is crucial. Providing clear, understandable information about ITP, its symptoms, management, and emergency protocols can empower patients and families, reduce anxiety, and foster a sense of control. This includes advising on avoiding anti-platelet medications, recognizing signs of severe bleeding, and understanding when to seek immediate medical attention.

• Support Groups and Counseling: Connecting patients and families with ITP-specific support groups (e.g., Platelet Disorder Support Association – PDSA) can provide invaluable emotional support, shared experiences, and practical advice for coping with the disease. Psychosocial counseling can also help families navigate the emotional challenges and improve communication [53].

• Financial and Occupational Impact: Chronic illness can lead to financial strain due to medical costs, time off work for appointments, or reduced work capacity due to fatigue or symptoms. Addressing these practical concerns through social work support or patient advocacy programs is important.

7.4 Special Populations

Certain patient populations with ITP require specialized considerations due to unique physiological or clinical circumstances.

• ITP in Pregnancy: ITP can complicate pregnancy due to increased bleeding risk for the mother and potential for neonatal thrombocytopenia (due to passive transfer of maternal anti-platelet antibodies across the placenta, although severe neonatal ITP is rare). Management during pregnancy focuses on balancing maternal and fetal safety, primarily using corticosteroids and IVIg. TPO-RAs are generally avoided due to limited safety data [54]. Delivery planning is critical, with consideration for vaginal versus Cesarean section based on maternal platelet count and potential fetal thrombocytopenia.

• ITP in the Elderly: Older adults with ITP often present with more comorbidities, are on multiple medications, and may have a higher risk of bleeding complications and treatment-related toxicities. Careful assessment of functional status, cognitive ability, and coexisting medical conditions is essential when selecting therapies to minimize adverse events [55].

• ITP and Infection Risk: Patients with ITP, especially those undergoing immunosuppressive therapies (corticosteroids, rituximab) or splenectomy, are at an increased risk of infections. Prophylactic vaccinations (influenza, pneumococcal, tetanus, HPV, Hepatitis B) are crucial, and prompt evaluation and management of any febrile illness are necessary. Travel medicine advice regarding endemic infections is also important.

• ITP and Thrombosis: While primarily a bleeding disorder, ITP patients have an increased risk of venous thromboembolism (VTE) and arterial thrombosis. This risk is further exacerbated by certain treatments (e.g., TPO-RAs, splenectomy) and co-existing conditions (e.g., malignancy, immobility). Balancing the risk of bleeding and thrombosis is a key challenge in managing ITP patients [29].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

8. Conclusion

Immune Thrombocytopenia is a multifaceted and heterogeneous autoimmune disorder characterized by complex pathophysiological mechanisms involving both accelerated platelet destruction and impaired platelet production. Significant advancements in our understanding of its etiology, immune dysregulation, and cellular pathways have transformed the diagnostic approach and, critically, expanded the therapeutic armamentarium. From the historical reliance on corticosteroids and splenectomy, the treatment landscape has evolved to include targeted therapies such as TPO-RAs, rituximab, and novel Syk inhibitors, offering more personalized and effective options for patients with chronic and refractory disease.

Despite these notable therapeutic strides, challenges persist. Diagnosing ITP remains a diagnosis of exclusion, necessitating meticulous clinical and laboratory evaluation to differentiate it from numerous secondary causes of thrombocytopenia. Furthermore, the variable natural course of the disease, particularly in adults, and the often-debilitating impact on patients’ quality of life underscore the need for a comprehensive, patient-centered approach to management that extends beyond merely normalizing platelet counts. Addressing fatigue, anxiety, and the psychosocial burden on patients and their families is paramount to achieving true treatment success.

Ongoing research continues to unravel the intricate mechanisms of immune dysregulation in ITP, paving the way for even more targeted and potentially curative therapies. The emergence of BTK inhibitors and FcRn inhibitors exemplifies the innovative directions in drug development. Future efforts will likely focus on identifying reliable biomarkers to predict response to specific therapies, further refining personalized treatment strategies, and developing interventions that truly restore immune tolerance rather than simply modulating platelet counts. Through continued research, collaborative care models, and a steadfast commitment to patient advocacy, the journey towards improved outcomes and enhanced quality of life for individuals living with ITP remains a critical endeavor in hematology.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

References

1. Harrington, W. J., & Hollingsworth, J. W. (1951). Thrombocytopenia in a normal subject following transfusion of blood from a patient with idiopathic thrombocytopenic purpura. Journal of Clinical Investigation, 30(4), 426–429.

2. Rodeghiero, F., Stasi, R., Gernsheimer, T., Michel, M., Provan, D., Arnold, D. M., … & Cines, D. B. (2009). Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood, 113(11), 2386-2393.

3. Provan, D., Stasi, R., Newland, A. C., Blanchette, V. S., Bussel, J. B., Cines, D. B., … & Rodeghiero, F. (2010). International consensus report on the management of immune thrombocytopenia. Blood, 115(2), 168-186.

4. Neunert, C., Lim, W., Crowther, M., Cohen, A., Solberg Jr, L., Smith, J., & Bussel, J. B. (2011). The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood, 117(16), 4190-4207.

5. McMillan, R., & Bussel, J. B. (2018). Platelet antibody tests in ITP. Blood, 131(25), 2727-2732.

6. Cines, D. B., & Blanchette, V. S. (2002). Immune thrombocytopenic purpura. New England Journal of Medicine, 346(13), 995-1008.

7. Stasi, R. (2020). Pathophysiology of immune thrombocytopenia: focus on thrombopoietin. Annals of Translational Medicine, 8(Suppl 1), S1.

8. Cooper, N., & Bussel, J. B. (2005). The pathogenesis and treatment of immune thrombocytopenic purpura: current status. Seminars in Hematology, 42(1), 12-22.

9. Nishimoto, M., Miyakawa, Y., Kataoka, N., Nishikawa, M., Kanakura, Y., & Koga, H. (2021). Complement activation in immune thrombocytopenia: a comprehensive review. International Journal of Molecular Sciences, 22(19), 10563.

10. Zhang, X., Li, X., Wu, X., & Deng, H. (2018). The role of NK cells in immune thrombocytopenia. Journal of Immunology Research, 2018, 4529329.

11. Ling, Y., Li, X., Wang, Y., Zhang, R., Guo, X., & Li, M. (2021). Regulatory T cells in immune thrombocytopenia. Frontiers in Immunology, 12, 697850.

12. Semple, J. W., & Provan, D. (2012). The pathophysiology of immune thrombocytopenia: current understanding and future prospects. Hematology/Oncology Clinics of North America, 26(2), 345-360.

13. Sun, L., Zhu, C., Jin, J., Zhang, C., & Ruan, C. (2018). Cytotoxic T lymphocytes in immune thrombocytopenia. Journal of Immunology Research, 2018, 8632617.

14. Ambruso, D. R., & Hays, T. (2016). Genetic insights into immune thrombocytopenia. Journal of Clinical Hematology and Oncology, 14(4), 165-171.

15. Al-Jabiri, F., & Al-Khouri, J. (2020). The role of HLA alleles in immune thrombocytopenia. Molecular and Cellular Biochemistry, 465(1-2), 1-10.

16. Wang, X., Hou, M., & Yang, R. (2019). The emerging role of cytokines in the pathogenesis and treatment of immune thrombocytopenia. Frontiers in Immunology, 10, 2595.

17. Wang, Q., Li, W., & Xu, Z. (2021). The PTPN22 gene polymorphism in immune thrombocytopenia: A systematic review and meta-analysis. Autoimmunity Reviews, 20(8), 102871.

18. George, J. N. (2009). How I treat immune thrombocytopenia. Blood, 114(18), 3764-3775.

19. Stasi, R., Stipa, E., Masi, M., Cecconi, M., Scimo, R., Paparatti, C., … & Rossi, E. (2007). Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. American Journal of Medicine, 120(12), 1076-1082.

20. Michel, M. (2018). Role of infections in immune thrombocytopenia. Hematology/Oncology Clinics of North America, 32(3), 469-482.

21. Veneri, D., De Matteis, G., & D’Andrea, M. (2020). Helicobacter pylori and immune thrombocytopenia: a systematic review and meta-analysis. International Journal of Infectious Diseases, 96, 1-7.

22. Aster, R. H., & Curtis, B. R. (2018). Drug-induced immune thrombocytopenia. New England Journal of Medicine, 379(19), 1838-1849.

23. Lee, E. J., Cines, D. B., Gernsheimer, T. B., Kessler, C., Michel, M., Miyakawa, Y., … & Stasi, R. (2021). COVID-19 vaccination and immune thrombocytopenia: a review of the evidence. Blood, 138(18), 1735-1746.

24. Kühne, T., Berchtold, S., & Imbach, P. (2003). Presenting features and diagnosis of immune thrombocytopenic purpura in childhood. Journal of Pediatrics, 143(6), 724-728.

25. Lambert, M. P., & Bussel, J. B. (2012). Immune thrombocytopenia in adults. New England Journal of Medicine, 366(16), 1545-1550.

26. Terrell, D. R., Vesely, S. K., Segal, J. B., Onwuemene, K. A., & George, J. N. (2010). The incidence of immune thrombocytopenic purpura in the adult population of the United States. American Journal of Hematology, 85(2), 174-177.

27. Moulis, G., Palmaro, A., Montastruc, F., Godeau, B., Sailler, L., & Lapeyre-Mestre, M. (2014). Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood, 124(21), 3332-3334.

28. Michel, M., & Godeau, B. (2019). Autoimmune diseases associated with immune thrombocytopenia. Seminars in Hematology, 56(3), 200-209.

29. Ruggeri, M., & Rodeghiero, F. (2018). Thrombotic risk in immune thrombocytopenia. Current Opinion in Hematology, 25(5), 415-420.

30. Sarode, R., & George, J. N. (2015). Diagnosis of thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 13(2), 136-140.

31. Berkman, N., Michaeli, Y., & Brenner, B. (2014). Pseudothrombocytopenia: a review. American Journal of Hematology, 89(9), 920-925.

32. Zulfiqar, A. A., & Inamo, J. (2018). Peripheral blood smear in immune thrombocytopenia. Expert Review of Hematology, 11(8), 653-662.

33. Cines, D. B., Bussel, J. B., Lieberman, H. A., & Stasi, R. (2009). The role of bone marrow examination in the diagnosis of immune thrombocytopenic purpura. Transfusion Medicine Reviews, 23(3), 195-201.

34. Cohen, Y. C., Djulbegovic, B., & Bussel, J. B. (2000). The natural history of immune thrombocytopenic purpura in adults: a systematic review. Journal of Thrombosis and Haemostasis, 98(8), 2246-2253.

35. Kuter, D. J., Bussel, J. B., Lyons, R. M., Lee, E., Conklin, G. T., Becker, B. D., … & Platelet Disorder Support Association (PDSA). (2019). The ITP Bleeding Assessment Tool (ITP-BAT): a valid and reliable instrument for measuring bleeding severity in immune thrombocytopenia. American Journal of Hematology, 94(12), 1358-1367.

36. Imbach, P., Kühne, T., Holladay, C., & Hitzler, J. (2010). Idiopathic thrombocytopenic purpura in childhood: from diagnosis to treatment. Seminars in Thrombosis and Hemostasis, 36(4), 398-406.

37. Buchanan, G. R., & Adix, L. (2002). Prognostic factors in childhood acute immune thrombocytopenic purpura. Blood, 99(5), 1836-1840.

38. Provan, D., Arnold, D. M., & Bussel, J. B. (2019). Updated international consensus report on the management of immune thrombocytopenia. Blood Advances, 3(22), 3728-3765.

39. Michel, M., & Cooper, N. (2010). Management of adults with primary immune thrombocytopenia. Blood, 115(1), 1-13.

40. Newton, N., & Stasi, R. (2018). Fatigue in immune thrombocytopenia: prevalence, impact, and management. Journal of Clinical Hematology and Oncology, 16(1), 17-23.

41. Ma, H. Y., Yang, S. G., Wang, X., Hou, Y., Ma, D., & Peng, J. (2017). Mechanisms of action of glucocorticoids in immune thrombocytopenia. Journal of Clinical Immunology, 37(1), 1-7.

42. Mazzucconi, M. G., Fazi, P., & Pati, M. (2007). Therapy for immune thrombocytopenia: a systematic review. Seminars in Hematology, 44(2), S12-S21.

43. Samuelsson, A., Towers, T. L., & Ravetch, J. V. (2001). Anti-inflammatory activity of IVIg mediated by FcgammaRIIb that requires sialylated Fc. Science, 291(5503), 1184-1186.

44. Kuter, D. J. (2018). The biology and physiology of thrombopoietin and thrombopoietin receptor agonists. Seminars in Hematology, 55(3), 111-125.

45. Kuter, D. J., Bussel, J. B., Newland, A., Wasser, J. S., Grainger, J. D., & Lyons, R. M. (2017). Results from the global, phase 3, randomized, double-blind, placebo-controlled clinical trial of avatrombopag in patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to prior treatment. Blood, 130(Supplement 1), 606.

46. Michel, M., & Kuter, D. J. (2012). Thrombotic risk with thrombopoietin-receptor agonists in immune thrombocytopenia. Blood, 120(15), 2951-2957.

47. Zaja, F., & Baccarani, M. (2009). Rituximab for immune thrombocytopenia. Blood, 113(18), 4165-4173.

48. Vianelli, N., Palandri, F., & Gamberi, B. (2005). Long-term follow-up of 100 splenectomized patients with immune thrombocytopenic purpura. American Journal of Hematology, 79(3), 209-214.

49. Bussel, J. B., Arnold, D. M., & Boxer, M. (2020). Fostamatinib for the treatment of adult chronic immune thrombocytopenia. Expert Review of Hematology, 13(1), 1-10.

50. Kuter, D., Bussel, J. B., & Collins, B. (2022). Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia. New England Journal of Medicine, 386(15), 1421-1431.

51. Stasi, R., & Bussel, J. B. (2022). FcRn inhibitors: a new class of agents for autoimmune diseases. Blood, 140(11), 1215-1226.

52. Borst, L., & Meijer, K. (2018). Antifibrinolytic agents in immune thrombocytopenia. Seminars in Hematology, 55(3), 164-169.

53. Bussel, J. B., & Kuter, D. J. (2018). Impact of patient advocacy groups on research and patient care in immune thrombocytopenia. Seminars in Hematology, 55(3), 170-174.

54. Webert, K. E., & Mittal, R. (2014). ITP in pregnancy: management challenges. Transfusion Medicine Reviews, 28(3), 159-166.

55. Ghanima, W., Godeau, B., & Bussel, J. B. (2020). ITP in the elderly: a challenging population. Blood, 136(26), 2999-3008.